Q1 Earnings Forecast for Immunome Issued By Lifesci Capital

Immunome, Inc. (NASDAQ:IMNM) – Lifesci Capital issued their Q1 2025 earnings estimates for shares of Immunome in a report released on Tuesday, March 11th. Lifesci Capital analyst C. Zhu expects that the company will post earnings of ($0.61) per share for the quarter. Lifesci Capital currently has a “Outperform” rating and a $20.00 price target on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome’s Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.62) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.90) EPS.

Other analysts have also recently issued research reports about the stock. Wedbush reiterated an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research note on Monday. Piper Sandler dropped their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $27.17.

Immunome Stock Performance

Shares of IMNM stock opened at $8.93 on Thursday. The company has a market capitalization of $712.41 million, a price-to-earnings ratio of -1.10 and a beta of 1.93. The company has a 50-day simple moving average of $10.06 and a 200 day simple moving average of $11.87. Immunome has a 52 week low of $8.39 and a 52 week high of $26.70.

Insider Activity

In related news, CEO Clay B. Siegall purchased 150,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the acquisition, the chief executive officer now owns 669,636 shares of the company’s stock, valued at $5,189,679. This trade represents a 28.87 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Enavate Sciences GP LLC bought a new stake in Immunome during the 4th quarter worth approximately $36,939,000. JPMorgan Chase & Co. boosted its stake in shares of Immunome by 2,540.4% in the 4th quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company’s stock valued at $6,888,000 after purchasing an additional 624,045 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Immunome by 10.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after purchasing an additional 324,614 shares during the last quarter. Granahan Investment Management LLC bought a new stake in shares of Immunome in the 4th quarter valued at $3,337,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Immunome by 2,696.5% in the 4th quarter. Renaissance Technologies LLC now owns 316,000 shares of the company’s stock valued at $3,356,000 after purchasing an additional 304,700 shares during the last quarter. 44.58% of the stock is owned by institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.